Aeolus Pharmaceuticals Inc. (OTCMKTS:AOLS) to Release Quarterly Earnings on Monday
Aeolus Pharmaceuticals (OTCMKTS:AOLS) last issued its quarterly earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.01) EPS for the quarter. The business had revenue of $0.13 million for the quarter. Aeolus Pharmaceuticals had a negative net margin of 283.29% and a negative return on equity of 151.30%. On average, analysts expect Aeolus Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of Aeolus Pharmaceuticals Inc. (OTCMKTS AOLS) opened at 0.07264 on Monday. Aeolus Pharmaceuticals Inc. has a 12 month low of $0.05 and a 12 month high of $0.27. The stock’s market capitalization is $11.05 million. The company’s 50 day moving average price is $0.09 and its 200-day moving average price is $0.13.
About Aeolus Pharmaceuticals
Aeolus Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on developing a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. As of September 30, 2016, the Company’s platform consisted of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke) and National Jewish Health (NJH).
Receive News & Ratings for Aeolus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeolus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.